中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

丁型肝炎研究进展

邹怀宾 任锋 陈煜 段钟平

引用本文:
Citation:

丁型肝炎研究进展

DOI: 10.3969/j.issn.1001-5256.2022.03.032
基金项目: 

大数据精准医疗高精尖创新中心项目 (1212040205)

国家自然科学基金 (81770611)

北京自然科学基金和北京市教委联合资助重点项目 (KZ202010025035)

利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:邹怀宾负责查阅文献和撰写论文;任锋、陈煜负责修改论文;段钟平负责拟定写作思路,指导撰写文章并最后定稿。
详细信息
    通信作者:

    段钟平,duan@ccmu.edu.cn

Research advances in hepatitis D

Research funding: 

Project of Advanced Innovation Center for Big Data-Based Precision Medicine (1212040205);

National Natural Science Foundation of China (81770611);

Key Project Jointly Funded by Beijing Natural Science Foundation and Beijing Municipal Commission of Education (KZ202010025035)

More Information
    Corresponding author: DUAN Zhongping, duan@ccmu.edu.cn(ORCID:0000-0002-8455-0426)
  • 摘要: HDV需要借助HBV才能感染肝细胞并传播。HBV感染基础上合并HDV感染会加快病情进展且患者预后更差,但目前HDV感染的危害与疾病负担被严重低估。本文总结了HDV感染的流行病学、临床表现、诊断及治疗等方面研究进展,以期为更多的临床医生提供参考。

     

  • [1] RIZZETTO M, CANESE MG, ARICÒ S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers[J]. Gut, 1977, 18(12): 997-1003. DOI: 10.1136/gut.18.12.997.
    [2] BOTELHO-SOUZA LF, VASCONCELOS M, DOS SANTOS AO, et al. Hepatitis delta: Virological and clinical aspects[J]. Virol J, 2017, 14(1): 177. DOI: 10.1186/s12985-017-0845-y.
    [3] HUGHES SA, WEDEMEYER H, HARRISON PM. Hepatitis delta virus[J]. Lancet, 2011, 378(9785): 73-85. DOI: 10.1016/S0140-6736(10)61931-9.
    [4] URBAN S, NEUMANN-HAEFELIN C, LAMPERTICO P. Hepatitis D virus in 2021: Virology, immunology and new treatment approaches for a difficult-to-treat disease[J]. Gut, 2021, 70(9): 1782-1794. DOI: 10.1136/gutjnl-2020-323888.
    [5] BESOMBES C, NJOUOM R, PAIREAU J, et al. The epidemiology of hepatitis delta virus infection in Cameroon[J]. Gut, 2020, 69(7): 1294-1300. DOI: 10.1136/gutjnl-2019-320027.
    [6] TOY M, AHISHALI E, YURDAYD1N C. Hepatitis delta virus epidemiology in the industrialized world[J]. AIDS Rev, 2020, 22(4): 203-212. DOI: 10.24875/AIDSRev.20000056.
    [7] LEMPP FA, NI Y, URBAN S. Hepatitis delta virus: Insights into a peculiar pathogen and novel treatment options[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(10): 580-589. DOI: 10.1038/nrgastro.2016.126.
    [8] STOCKDALE AJ, KREUELS B, HENRION M, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis[J]. J Hepatol, 2020, 73(3): 523-532. DOI: 10.1016/j.jhep.2020.04.008.
    [9] ZHANG Z, URBAN S. New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies[J]. J Hepatol, 2021, 74(3): 686-699. DOI: 10.1016/j.jhep.2020.11.032.
    [10] CHEN HY, SHEN DT, JI DZ, et al. Prevalence and burden of hepatitis D virus infection in the global population: A systematic review and meta-analysis[J]. Gut, 2019, 68(3): 512-521. DOI: 10.1136/gutjnl-2018-316601.
    [11] MIAO Z, ZHANG S, OU X, et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection[J]. J Infect Dis, 2020, 221(10): 1677-1687. DOI: 10.1093/infdis/jiz633.
    [12] SHEN DT, JI DZ, CHEN HY, et al. Hepatitis D: Not a rare disease anymore: Global update for 2017-2018[J]. Gut, 2020, 69(4): 786-788. DOI: 10.1136/gutjnl-2019-318691.
    [13] WU S, ZHANG Y, TANG Y, et al. Molecular epidemiology and clinical characteristics of hepatitis delta virus (HDV) infected patients with elevated transaminases in Shanghai, China[J]. BMC Infect Dis, 2020, 20(1): 565. DOI: 10.1186/s12879-020-05275-1.
    [14] ROULOT D, BRICHLER S, LAYESE R, et al. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta[J]. J Hepatol, 2020, 73(5): 1046-1062. DOI: 10.1016/j.jhep.2020.06.038.
    [15] HERCUN J, KOH C, HELLER T. Hepatitis delta: Prevalence, natural history, and treatment options[J]. Gastroenterol Clin North Am, 2020, 49(2): 239-252. DOI: 10.1016/j.gtc.2020.01.004.
    [16] DIAS J, HENGST J, PARROT T, et al. Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells[J]. J Hepatol, 2019, 71(2): 301-312. DOI: 10.1016/j.jhep.2019.04.009.
    [17] THAM C, KAH J, TAN AT, et al. Hepatitis delta virus acts as an immunogenic adjuvant in hepatitis B virus-infected hepatocytes[J]. Cell Rep Med, 2020, 1(4): 100060. DOI: 10.1016/j.xcrm.2020.100060.
    [18] VIEIRA BARBOSA J, SAHLI R, AUBERT V, et al. Demographics and outcomes of hepatitis B and D: A 10-year retrospective analysis in a Swiss tertiary referral center[J]. PLoS One, 2021, 16(4): e0250347. DOI: 10.1371/journal.pone.0250347.
    [19] SAGNELLI C, SAGNELLI E, RUSSO A, et al. HBV/HDV co-infection: Epidemiological and clinical changes, recent knowledge and future challenges[J]. Life (Basel), 2021, 11(2): 169. DOI: 10.3390/life11020169.
    [20] BRICHLER S, LE GAL F, BUTT A, et al. Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify hepatitis delta virus viremia[J]. Clin Gastroenterol Hepatol, 2013, 11(6): 734-740. DOI: 10.1016/j.cgh.2013.01.025.
    [21] LU XX, YI Y, SU QD, et al. Expression and purification of recombinant hepatitis delta virus (HDV) antigen for use in a diagnostic ELISA for HDV infection using the high-density fermentation strategy in Escherichia coli[J]. Biomed Environ Sci, 2016, 29(6): 417-423. DOI: 10.3967/bes2016.054.
    [22] CHEN X, OIDOVSAMBUU O, LIU P, et al. A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians[J]. Hepatology, 2017, 66(6): 1739-1749. DOI: 10.1002/hep.28957.
    [23] CHEN GH, ZHANG MD, HUANG W. Hepatitis delta virus superinfection in Guangzhou area[J]. Chin Med J (Engl), 1990, 103(6): 451-454. http://www.ncbi.nlm.nih.gov/pubmed/2119957
    [24] JIANG YZ, ZHANG MC, TIAN RG, et al. Expression of the hepatitis Delta antigen in prokaryotic cell and evaluation of its application as an EIA diagnostic reagent[J]. Chin J Exp Clin Virol, 2006, 20(2): 38-41. DOI: 10.3760/cma.j.issn.1003-9279.2006.02.012.

    江永珍, 张明程, 田瑞光, 等. 丁型肝炎病毒抗原的原核表达及抗原性分析[J]. 中华实验和临床病毒学杂志, 2006, 20(2): 38-41. DOI: 10.3760/cma.j.issn.1003-9279.2006.02.012.
    [25] SHEN L, GU Y, SUN L, et al. Development of a hepatitis delta virus antibody assay for study of the prevalence of HDV among individuals infected with hepatitis B virus in China[J]. J Med Virol, 2012, 84(3): 445-449. DOI: 10.1002/jmv.23212.
    [26] GU WJ, HUANG WJ, ZHOU C, et al. Evaluate the HDV diagnostic kits (EIA) with HBV surface antigen positive sera[J]. Chin Pharm Affairs, 2011, 25(9): 866-868, 879. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYS201109009.htm

    辜文洁, 黄维金, 周诚, 等. 不同HDV诊断试剂对HBsAg阳性样品的检测分析[J]. 中国药事, 2011, 25(9): 866-868, 879. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYS201109009.htm
    [27] TAYLOR JM. Infection by hepatitis delta virus[J]. Viruses, 2020, 12(6): 648. DOI: 10.3390/v12060648.
    [28] LIN GY, WU YL, WANG CS, et al. Performance of commercially available anti-HDV enzyme-linked immunosorbent assays in Taiwan[J]. Virol J, 2020, 17(1): 76. DOI: 10.1186/s12985-020-01355-5.
    [29] STELZL E, CIESEK S, CORNBERG M, et al. Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: A European multicenter study[J]. J Clin Virol, 2021, 142: 104932. DOI: 10.1016/j.jcv.2021.104932.
    [30] KOH C, HELLER T, GLENN JS. Pathogenesis of and new therapies for hepatitis D[J]. Gastroenterology, 2019, 156(2): 461-476. DOI: 10.1053/j.gastro.2018.09.058.
    [31] BATTEGAY M, SIMPSON LH, HOOFNAGLE JH, et al. Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis[J]. J Med Virol, 1994, 44(4): 389-392. DOI: 10.1002/jmv.1890440413.
    [32] FARCI P, MANDAS A, COIANA A, et al. Treatment of chronic hepatitis D with interferon alfa-2a[J]. N Engl J Med, 1994, 330(2): 88-94. DOI: 10.1056/NEJM199401133300202.
    [33] CASTELNAU C, LE GAL F, RIPAULT MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up[J]. Hepatology, 2006, 44(3): 728-735. DOI: 10.1002/hep.21325.
    [34] ABDRAKHMAN A, ASHIMKHANOVA A, ALMAWI WY. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis[J]. Antiviral Res, 2021, 185: 104995. DOI: 10.1016/j.antiviral.2020.104995.
    [35] SHELDON J, RAMOS B, TORO C, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?[J]. Antivir Ther, 2008, 13(1): 97-102. http://med.wanfangdata.com.cn/DocDeliveryNstl/Index/PeriodicalPaper_JJ024367317
    [36] YURDAYDIN C, BOZKAYA H, ONDER FO, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine+interferon vs interferon[J]. J Viral Hepat, 2008, 15(4): 314-321. DOI: 10.1111/j.1365-2893.2007.00936.x.
    [37] KABAÇAM G, ONDER FO, YAKUT M, et al. Entecavir treatment of chronic hepatitis D[J]. Clin Infect Dis, 2012, 55(5): 645-650. DOI: 10.1093/cid/cis459.
    [38] WEDEMEYER H, YURDAYDÌN C, DALEKOS GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta[J]. N Engl J Med, 2011, 364(4): 322-331. DOI: 10.1056/NEJMoa0912696.
    [39] ABBAS Z, MEMON MS, UMER MA, et al. Co-treatment with pegylated interferon alfa-2a and entecavir for hepatitis D: A randomized trial[J]. World J Hepatol, 2016, 8(14): 625-631. DOI: 10.4254/wjh.v8.i14.625.
    [40] WEDEMEYER H, YURDAYDIN C, HARDTKE S, et al. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-Ⅱ): A randomised, placebo controlled, phase 2 trial[J]. Lancet Infect Dis, 2019, 19(3): 275-286. DOI: 10.1016/S1473-3099(18)30663-7.
    [41] BOGOMOLOV P, ALEXANDROV A, VORONKOVA N, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study[J]. J Hepatol, 2016, 65(3): 490-498. DOI: 10.1016/j.jhep.2016.04.016.
    [42] LOGLIO A, FERENCI P, UCEDA RENTERIA SC, et al. Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients[J]. J Hepatol, 2019, 71(4): 834-839. DOI: 10.1016/j.jhep.2019.07.003.
    [43] WEDEMEYER H, SCHÖNEWEIS K, BOGOMOLOV P, et al. 48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection[J]. J Hepatol, 2020, 73(Suppl 1): s52-s53. http://www.sciencedirect.com/science/article/pii/S0168827820306516
    [44] CHAN H, AHN SH, CHANG TT, et al. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B)[J]. J Hepatol, 2016, 64(5): 1011-1019. DOI: 10.1016/j.jhep.2015.12.018.
    [45] ETZION O, HAMID S, LURIE Y, et al. End of study results from LIMT HDV study: 36% durable virologic response at 24 weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection[J]. J Hepatol, 2019, 70(Suppl 1): e32.
    [46] KOH C, HERCUN J, RAHMAN F, et al. A phase 2 study of peginterferon lambda, lonafarnib and ritonavir for 24 weeks: End-of-treatment results from the lift HDV study[J]. J Hepatol, 2020, 73: s130. http://www.sciencedirect.com/science/article/pii/S0168827820307741
    [47] BALDRIDGE MT, LEE S, BROWN JJ, et al. Expression of Ifnlr1 on intestinal epithelial cells is critical to the antiviral effects of interferon lambda against norovirus and reovirus[J]. J Virol, 2017, 91(7): e02079-16. DOI: 10.1128/JVI.02079-16.
    [48] KOH C, CANINI L, DAHARI H, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: A proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial[J]. Lancet Infect Dis, 2015, 15(10): 1167-1174. DOI: 10.1016/S1473-3099(15)00074-2.
    [49] BERNDT N, HAMILTON AD, SEBTI SM. Targeting protein prenylation for cancer therapy[J]. Nat Rev Cancer, 2011, 11(11): 775-791. DOI: 10.1038/nrc3151.
    [50] YURDAYDIN C, KESKIN O, KALKAN Ç, et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study[J]. Hepatology, 2018, 67(4): 1224-1236. DOI: 10.1002/hep.29658.
    [51] BEILSTEIN F, BLANCHET M, VAILLANT A, et al. Nucleic acid polymers are active against hepatitis delta virus infection in vitro[J]. J Virol, 2018, 92(4): e01416-17. DOI: 10.1128/JVI.01416-17.
    [52] VAILLANT A. REP 2139: Antiviral mechanisms and applications in achieving functional control of HBV and HDV infection[J]. ACS Infect Dis, 2019, 5(5): 675-687. DOI: 10.1021/acsinfecdis.8b00156.
  • 加载中
计量
  • 文章访问数:  679
  • HTML全文浏览量:  130
  • PDF下载量:  108
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-07-26
  • 录用日期:  2021-08-10
  • 出版日期:  2022-03-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回